ABIVAX Société Anonyme (EPA:ABVX)
France · Delayed Price · Currency is EUR | Market Cap | 8.35B +2,007.7% |
| Revenue (ttm) | 4.57M -63.2% |
| Net Income | -336.10M |
| EPS | -4.83 |
| Shares Out | 79.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,516 |
| Average Volume | 114,755 |
| Open | 105.20 |
| Previous Close | 105.50 |
| Day's Range | 103.30 - 106.40 |
| 52-Week Range | 5.00 - 132.00 |
| Beta | -0.19 |
| RSI | 53.93 |
| Earnings Date | May 25, 2026 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.
Financial StatementsNews
Abivax Repurchases Royalty Certificates And Prices $45M ADS Offering To Strengthen Balance Sheet
(RTTNews) - Abivax SA (ABVX), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, announced the repurchase of its outstanding royalty certificates and the pr...
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Abivax call volume above normal and directionally bullish
Bullish option flow detected in Abivax (ABVX) with 1,405 calls trading, 1.3x expected, and implied vol increasing over 1 point to 94.14%. May-26 190 calls and 5/1 weekly 130 calls
Abivax to Present Data on Obefazimod at Digestive Disease Week®
Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical A...
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF
Oddo BHF analyst Martial Descoutures raised the firm’s price target on Abivax (ABVX) to EUR 120 from EUR 88 and keeps an Outperform rating on the shares. The firm views
This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?
Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.
Abivax appoints Michael Nesrallah as chief commercial officer
Abivax (ABVX) has appointed Michael Nesrallah as its chief commercial officer, Nesrallah will lead global commercial strategy and launch preparation as the company advances toward potential regulatory...
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – Ap...
2 Healthcare Stocks That Could Soar Over the Next 5 Years
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
• Abivax stock is taking a hit today. Why is ABVX stock falling?
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French bi...
Abivax price target raised to $148 from $142 at Barclays
Barclays raised the firm’s price target on Abivax (ABVX) to $148 from $142 and keeps an Overweight rating on the shares. The firm says the “clean” Data and Safety Monitoring
– Abivax SA American Depositary Shares options imply 8.3% move in share price post-earnings
Pre-earnings options volume in – Abivax (ABVX) SA American Depositary Shares is normal with calls leading puts 5:4. Implied volatility suggests the market is anticipating a move near 8.3%, or
2 Healthcare Stocks to Buy Before They Get Bought Out
Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions.
Abivax initiated with a Buy at Jefferies
Jefferies initiated coverage of Abivax (ABVX) with a Buy rating and $160 price target The firm views the company’s obefazimod as “differentiated” drug for ulcerative colitis. Abivax’s maintenance read...
Abivax spokesperson denies takeover rumors reported by French media
Biotechnology company Abivax dismissed information published by French media publication "La Lettre" saying it had granted AstraZeneca exclusive access to confidential information until March ...
Abivax says ‘we deny the rumors’ to Bloomberg after takeover report
10:09 EDT Abivax (ABVX) says ‘we deny the rumors’ to Bloomberg after takeover report
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli...
Abivax jumps 15% to $129.11 after report of exclusivity with AstraZeneca
05:45 EDT Abivax (ABVX) jumps 15% to $129.11 after report of exclusivity with AstraZeneca (AZN)
AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports
Abivax (ABVX) has granted AstraZeneca (AZN) an exclusive period through March 23 to access confidential information and formalize a potential takeover offer, La Lettre’s Matthew Protard reports. After...
Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year
Abivax's shares have skyrocketed since David Cohen's fund first bought some shares. The company's leading candidate is promising, but there is substantial risk as well.
2 Reasons Abivax Stock Could 10X by 2036
Abivax's leading candidate could be a breakthrough treatment in ulcerative colitis. The medicine will likely target several other immunology conditions as well.
Abivax initiated with an Underperform at Wedbush
Wedbush initiated coverage of Abivax (ABVX) with an Underperform rating and $110 price target
Wedbush initiates Abivax with an Underperform, urges caution
As previously reported, Wedbush initiated coverage of Abivax (ABVX) with an Underperform rating and $110 price target The firm notes Abivax is a clinical-stage biopharmaceutical company developing tre...